Investor Relations

Press Releases

<< Back Printer Friendly Version View printer-friendly version
Conformis Reports First Quarter 2021 Financial Results

BILLERICA, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2021.

First Quarter 2021 Summary

  • Total revenue of $13.8 million, a decrease of 16% year-over-year on a reported basis and 17% on a constant currency basis.
  • Product revenue of $13.7 million, a decrease of 16% year-over-year on a reported basis and 17% on a constant currency basis.
  • Conformis Hip System revenue up 49% year-over-year to $0.7 million.
  • Gross margin of 45%, an increase of 80 basis points year-over-year.
  • Total operating expenses remained flat year-over-year.
  • Closed on an $85 million stock offering.
  • 510(k) application for Conformis’ new standard knee submitted to the FDA for review.
  • Subsequent to quarter-end, received FDA 510(k) clearance for patient-specific instrumentation associated with the Stryker development agreement.

Executive Commentary – Mark Augusti, President and CEO

"The year is off to a good start. We met our expectations for business activity in the quarter as COVID-19 headwinds impacted elective procedures to the degree we anticipated. Despite these continuing headwinds for our industry, we are pleased with the progress of vaccine adoption nationwide and, as a result, remain cautiously optimistic that we will see procedure levels get back to normal in the second half of 2021. This anticipated acceleration in activity is timed well for our planned product introductions, which remain on track. We are in a great financial position, especially in light of the $11 million we expect to receive for achieving the final milestone under the Stryker development agreement. Having completed the development phase of the project with Stryker, we can now focus on manufacturing and supplying patient-specific instrumentation for Stryker. We will also continue to develop our hip portfolio, which grew nicely in the quarter, and continue preparing for the launch of our new knee offering, which will target the ASC segment.”

  Three months ended March 31, Increase/(decrease)
($, in thousands) 2021 2020 $ Change % Change % Change
        (as reported) (constant currency)
United States $ 11,604   $ 13,827   $ (2,223 ) (16 )% (16 )%
Rest of world 2,107   2,463   (356 ) (14 )% (22 )%
Product revenue 13,711   16,290   (2,579 ) (16 )% (17 )%
Royalty revenue 124   185   (61 ) (33 )% (33 )%
Total revenue $ 13,835   $ 16,475   $ (2,640 ) (16 )% (17 )%

First Quarter 2021 Highlights


  • Decrease in revenue year-over-year was driven primarily by lower volume due to the impact of the COVID-19 pandemic on elective procedures.
  • Conformis Hip System revenue for the first quarter of 2021, which were all in the United States, were up 49% to $0.7 million.

Gross Margin

  • Total gross profit decreased $1.0 million to $6.2 million, or 45% of revenue, in the first quarter of 2021, compared to $7.2 million, or 44% of revenue, in the first quarter of 2020.
  • The 80 basis point increase in gross margin year-over-year was driven primarily by lower cancelled case inventory expense, partially offset by manufacturing variances as a result of lower production volume.

Operating Expenses

  • Total operating expenses of $15.3 million were flat year-over-year.
  • Sales and marketing expenses declined $1.5 million due to lower marketing event, program, and advertising expenses, sales commissions, and travel expenses.
  • Research and development expenses increased $0.6 million primarily driven by personnel costs to support our new product pipeline.
  • General and administrative expenses increased $0.9 million primarily driven by higher professional fees related to the protection of our intellectual property.

Net Loss

  • Net loss was $11.5 million, or $0.09 per basic and diluted share, in the first quarter of 2021, compared to a net loss of $9.4 million, or $0.14 per basic and diluted share, in the same period last year.
  • Foreign currency exchange loss was $1.8 million in the first quarter of 2021, compared to $0.7 million in the same period last year.
  • Weighted average basic and diluted shares outstanding of 131.3 million for the first quarter of 2021, compared to 67.3 million for the same period last year.

Capital Structure and Liquidity

  • Cash and cash equivalents totaled $104.6 million as of March 31, 2021, compared to $28.7 million as of December 31, 2020.
  • As previously announced on February 12, 2021, the Company generated gross proceeds of approximately $85 million in an underwritten public offering of 80,952,381 shares of common stock at $1.05 per share. Net proceeds were approximately $79.6 million.


  • We expect our second quarter product revenue to improve sequentially from the first quarter and to be in the range of $14.0 million to $14.5 million.
  • We believe elective procedure volumes will improve in the third quarter and approach 2019 levels in the fourth quarter as vaccines become more widely available.

Note on Non-GAAP Financial Measures

In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company provides certain information regarding the Company's financial results or projected financial results on a non-GAAP "constant currency basis." This information estimates the impact of changes in foreign currency rates on the translation of the Company's current or projected future period financial results as compared to the applicable comparable period. This impact is derived by taking the adjusted current or projected local currency results and translating them into U.S. dollars based upon the foreign currency exchange rates for the applicable comparable period. It does not include any other effect of changes in foreign currency rates on the Company's results or business. Non-GAAP information is not a substitute for, and is not superior to, information presented on a GAAP basis. Company management uses these non-GAAP measures internally to measure operational performance.


As previously announced, Conformis will conduct a webcast today at 4:30 PM Eastern Time. Management will discuss financial results and strategic matters. The webcast will be live at

The online archive of the webcast will be available on the Company's website for 30 days.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient's unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit To receive future releases in e-mail alerts, sign up at

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, including statements about the impact of the novel coronavirus (COVID-19) pandemic and the actions we are taking and planning in response, our planned launch of a new program aimed at developing a knee replacement offering targeted at hospital outpatient and ambulatory surgery centers, the anticipated timing of our product launches, whether or when restrictions on elective surgeries will be relaxed and demand for procedures will increase, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these terms or other and similar expressions are intended to identify forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to the novel coronavirus pandemic and the response to the pandemic; whether our cash resources will be sufficient to fund our continuing operations for the periods anticipated; risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the "Risk Factors" sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and other public filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Consolidated Statements of Operations
(in thousands, except share and per share data)
  Three Months Ended March 31,
  2021   2020
Product $ 13,711     $ 16,290  
Royalty and licensing 124     185  
Total revenue 13,835     16,475  
Cost of revenue 7,662     9,261  
Gross profit 6,173     7,214  
Operating expenses      
Sales and marketing 5,113     6,563  
Research and development 3,540     2,990  
General and administrative 6,666     5,736  
Total operating expenses 15,319     15,289  
Loss from operations (9,146 )   (8,075 )
Other income and expenses      
Interest income 18     35  
Interest expense (594 )   (574 )
Foreign currency exchange transaction loss (1,761 )   (714 )
Total other expenses (2,337 )   (1,253 )
Loss before income taxes (11,483 )   (9,328 )
Income tax provision 23     25  
Net loss $ (11,506 )   $ (9,353 )
Net loss per share      
Basic and diluted $ (0.09 )   $ (0.14 )
Weighted average common shares outstanding      
Basic and diluted 131,300,157     67,274,391  

Consolidated Balance Sheets
(in thousands, except share and per share data)
  March 31, 2021   December 31, 2020
Assets  (unaudited)     
Current Assets      
Cash and cash equivalents $ 104,597     $ 28,673  
Accounts receivable, net 8,223     8,515  
Royalty and licensing receivable 131     1,256  
Inventories, net 13,341     12,585  
Prepaid expenses and other current assets 2,587     2,315  
Total current assets 128,879     53,344  
Property and equipment, net 11,547     12,240  
Operating lease right-of-use assets 4,903     5,215  
Other Assets      
Restricted cash 462     462  
Other long-term assets 229     239  
Total assets $ 146,020     $ 71,500  
Liabilities and stockholder's equity      
Current liabilities      
Accounts payable $ 5,005     $ 4,918  
Accrued expenses 6,357     7,213  
Operating lease liabilities 1,658     1,620  
Advance on research and development 2,651     3,168  
Contract liability 14,000     14,000  
Total current liabilities 29,671     30,919  
Long-term debt, less debt issuance costs 25,172     25,003  
Operating lease liabilities 3,852     4,206  
Total liabilities 58,695     60,128  
Commitments and contingencies      
Stockholders' equity      
Preferred stock, $0.00001 par value:      
Authorized: 5,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued and outstanding as of March 31, 2021 and December 31, 2020      
Common stock, $0.00001 par value:      
Authorized: 200,000,000 shares authorized at March 31, 2021 and December 31, 2020; 182,428,111 and 95,546,577 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively 2     1  
Additional paid-in capital 629,622     543,809  
Accumulated deficit (539,944 )   (528,438 )
Accumulated other comprehensive loss (2,355 )   (4,000 )
Total stockholders' equity 87,325     11,372  
Total liabilities and stockholders' equity $ 146,020     $ 71,500  

Investor Relations 
(781) 374-5598

Primary Logo

Source: Conformis, Inc.